Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan.
Nucl Med Biol. 2013 Apr;40(3):437-41. doi: 10.1016/j.nucmedbio.2012.11.007. Epub 2013 Jan 23.
In patients with unresectable HCC, transcatheter arterial chemoembolization (TACE) is a widely used treatment. Recently, as an alternative treatment modality for HCC, transcatheter arterial embolization with radioisotopes has been investigated. In this study, we compared the therapeutic efficacy of an intra-hepatic arterial injection of Re-188-MN-16ET-lipiodol and the TACE method in rats with liver tumors.
Twelve male rats bearing hepatic tumors were divided into three groups to evaluate the efficacy of treatment (four in each group). Group 1 received an intra-hepatic arterial injection of 0.2mCi of Re-188-MN-16ET-lipiodol; group 2 received epirubicin (0.5mg/kg) and 0.1ml of lipiodol emulsion; group 3 received 0.1ml of normal saline and served as the control group. Tumor size was measured by liver sonography before injection, at two weeks, four weeks and eight weeks after injection. Survival time was calculated from the day of treatment to 56days after treatment by the life-table method. The response to treatment and the survival time in each group were evaluated and compared.
All rats treated with Re-188 MN-16ET-lipiodol showed good response to the therapy. Their tumor size decreased and all rats survived over eight weeks. All rats treated with epirubicin plus lipiodol survived over 8weeks; however, two rats (50%) showed increased tumor size in the 8th week. As for the control group (rats treated with normal saline), all rats survived less than 37days with continuous tumor growth.
Results showed that Re-188-MN-16ET-lipiodol can be a potential therapeutic pharmaceutical for the treatment of liver tumors.
在无法切除的 HCC 患者中，经导管动脉化疗栓塞（TACE）是一种广泛使用的治疗方法。最近，作为 HCC 的替代治疗方法，放射性同位素经导管动脉栓塞术已被研究。在这项研究中，我们比较了放射性核素 Re-188-MN-16ET-碘化油肝内动脉注射与 TACE 方法在荷肝癌大鼠中的治疗效果。
12 只雄性大鼠荷肝肿瘤，分为三组评价治疗效果（每组 4 只）。第 1 组接受 0.2mCi 的 Re-188-MN-16ET-碘化油肝内动脉注射；第 2 组接受表柔比星（0.5mg/kg）和 0.1ml 碘化油乳剂；第 3 组接受 0.1ml 生理盐水作为对照组。注射前、注射后 2 周、4 周和 8 周进行肝脏超声测量肿瘤大小。采用寿命表法从治疗日计算至治疗后 56 天的生存时间。评价和比较各组的治疗反应和生存时间。
所有接受 Re-188 MN-16ET-碘化油治疗的大鼠均对治疗有良好的反应。肿瘤大小减小，所有大鼠均存活超过 8 周。所有接受表柔比星加碘化油治疗的大鼠均存活超过 8 周；然而，有 2 只大鼠（50%）在第 8 周肿瘤增大。对于对照组（生理盐水治疗的大鼠），所有大鼠均存活不到 37 天，肿瘤持续生长。
结果表明，Re-188-MN-16ET-碘化油可能是治疗肝癌的一种有潜力的治疗药物。
